

2021 Impact Report

aMoon
ACCELERATING CURE



We are in the age of discovery, seizing a unique moment in time.

WE ARE LIVING THROUGH

A Scientific and Technological Revolution

that is transforming healthcare as we know it - creating opportunities to confront the most pressing challenges facing modern day health systems.

aMoon is here to accelerate this change.



aMoon
ACCELERATING CURE

Table of Contents

Chapter One - 6
Investing in the Future of Health

Chapter Two - 16
aMoon at a Glance

Chapter Three - 22
Year in Review

Chapter Four - 25
Impact Thesis

Chapter Five - 38
Investor Additionality

Chapter Six - 49
Our Impact Management Frameworks

Chapter Seven - 57
Our People

Chapter Eight - 62
Disclaimer

Managing Partner Forward



aMoon was founded in 2017 to harness the rapid convergence of healthcare and technology with the mission of Accelerating Cure. With this goal in mind, we work to fund pioneering solutions that tackle healthcare's most pressing challenges while simultaneously producing exceptional returns for our LPs. At aMoon, we see these goals naturally align, as creating long-lasting impact and sustainable value is deeply connected to our ability to advance technologies that help people live healthier, longer, and better lives.

Our focus on impact allows us to form a common language with our partners and stakeholders, which connects us more deeply to the key innovators in the healthcare value chain. By engaging with ESG principles, we become better investors.

Investors in the private and public markets are increasingly looking to invest in companies that embed ESG into their core business practices. As regulators in Europe and the US plan to require investors to be ESG compliant, we aim to not only be prepared, but to remain ahead of the curve.

A large focus of our activities in 2021 revolved around creating the framework to incorporate ESG considerations into our investment activities, in line with industry guidance and the United Nations Sustainable Development Goals. I'm proud to say that we have built an engine that embeds ESG into aMoon's internal operations, our investment outlook, and our due diligence process.

Impact is at the core of our mission and the cornerstone of everything we do at aMoon. I believe that the work we have done over the course of this past year to enhance our impact management has pushed us further along our mission to advance solutions that will help improve access to care, quality of care, and cost of care to ***Accelerate Cure.***

Thank you,

Dr. Yair Schindel

Managing Partner, aMoon Fund



Chapter 01

Investing in the Future of Health

Our Vision for the Future of HealthTech

Discoveries are being made quicker. Healthcare is no longer a place where we need to wait 20 years to see a scientific discovery make a real impact on peoples' lives. We are seeing this revolution play out before our eyes, and it is exhilarating.

THE 5 CRUCIAL A'S DRIVING THE HEALTHTECH REVOLUTION:



ACCESSIBILITY

The advent of digital platforms such as telemedicine is creating a tremendous impact on health equity and a more democratized system of care.



AFFORDABILITY

One of the most valuable aspects of digital health is its power to dramatically reduce the cost of care, which in turn dramatically increases patients' capacity to engage and utilize existing treatments.



ACCURACY

We are witnessing the arrival of digital instruments that help us detect and study disease with levels of precision and personalization that were unimaginable just a few years ago.



ADVANCEMENTS

Empowering physicians and their patients to get ahead of disease by enabling early detection and prevention, which is crucial to improving long term healthcare outcomes.



ACCELERATING CURE

Healthcare innovation no longer requires decades-long research and development processes to impact peoples' lives. This exciting and transformative revolution is happening right before our eyes.

Pushing the Boundaries of Science to Accelerate Cure

aMoon portfolio companies are harnessing the power of proteomics, RNA, blood biomarkers, our immune system and more in order to cure diseases and save lives.

HARNESSING IMMUNE CELLS TO CURE DISEASE


Targeting the immune system by activating it to fight diseases such as cancer or modulating it in order to treat immunological diseases.

NECTINTx · Adicet Bio · ALTRUBIO · Biologic Design · KNOW

PRECISELY TARGETING CANCER CELLS

Developing tailor-made therapies that address specific patient and tumor characteristics.

viracta · ayala · nanoGhost



INNOVATIVELY TARGETING FUNDAMENTAL CELLULAR PROCESSES

Developing tools and therapies by tackling universal molecular processes in the cell (DNA, RNA, protein).

CAVOS BIOTECHNOLOGIES · STEALTH · MiNA Therapeutics · biosplice · seer

SIMPLE BLOOD TEST TO ANALYZE BIOMARKERS & DETECT DISEASE

Creating tools and technologies which will enable and improve early detection of disease through blood tests as well as better treatment selection.

METASIGHT · scipher MEDICINE · SOPHiA™ · MOBILion SYSTEMS, INC. · prognomiQ

Harvesting a deep blue ocean of innovation to revolutionize healthcare.



As healthcare costs rise to unsustainable levels and life spans increase, there is an acute need and unprecedented potential for technology to revolutionize healthcare. The convergence of biology and technology has created enormous potential to improve the quality, affordability and access to healthcare. It is time to realize the potential for HealthTech to not only extend life, but to improve our quality of life: to provide proactive, not just reactive care. To prevent, not only to treat.

RNA therapies to activate genes and cure cancer and other diseases

CASE STUDY

MiNA Therapeutics

Activating RNA (RNAa) is an entirely new class of medicines with potential to generate a variety of transformational treatments for patients across a wide range of diseases, from cancer to rare genetic disorders and more.

MiNA Therapeutics has developed a first-in-class RNAa therapy that activates the immune response in the tumor and has demonstrated unprecedented initial results for patients with advanced liver cancer.

IMPACT PILLARS


SAVE & EXTEND LIVES

PARADIGM SHIFTING BREAKTHROUGHS

CASE STUDY

MiNA Therapeutics

RNA THERAPIES TO ACTIVATE GENES AND CURE CANCER AND OTHER DISEASES



42k+
PEOPLE DIAGNOSED WITH LIVER CANCER IN THE US PER YEAR

~80%
OF PROTEINS ARE UNDRUGGABLE BY CONVENTIONAL MEDICINES

50K
POTENTIAL GENE TARGETS

$2.4M
RNAa PRODUCT SEQUENCES

UP TO
$1.25B
VALUE OF RECENTLY SIGNED RESEARCH COLLABORATION WITH ELI LILLY

Source(s): MiNA company data, 2022; American Society of Clinical Oncology, 2021

CASE STUDY

MDClone

Navigating data in a health system can be challenging, expensive, and time-consuming. Answering simple healthcare related questions can take months or longer due to siloed systems, complex data models, privacy regulations, and limited dedicated resources.

The MDClone ADAMS Platform is a powerful, self-service data analytics environment empowering any user to securely organize and access information, explore ideas, and find insights that power research, drive better patient outcomes, and create impactful healthcare innovation. Within the platform, users can quickly ask questions, refine queries and explore trends and patterns all while protecting patient privacy with groundbreaking synthetic data technology. MDClone's synthetic data generation is non-reversible, creating artificial data that replicates the statistical characteristics and correlations of original data sets.

MDClone provides the tools – and underlying technology – to integrate healthcare data from disparate sources and provide never-before possible clinical and operational insights for health systems, life science organizations, and healthcare technology companies.

IMPACT PILLARS

PARADIGM SHIFTING BREAKTHROUGHS

Democratizing healthcare big data

CASE STUDY

MDClone

DEMOCRATIZING HEALTHCARE BIG DATA



50M
PATIENT DATAPOINTS AVAILABLE IN MDCLONE'S SYNTHETIC DATA ENGINE

85+
ENTREPRENEURS UTILIZING SYNTHETIC DATA

$15M
ANNUAL COST SAVINGS AT INTERMOUNTAIN HEALTHCARE (MDCLONE PARTNER)

12
ELECTRONIC MEDICAL RECORD SYSTEMS INTEGRATED WITH THE MDCLONE PLATFORM

350+
RESEARCH PROJECTS UNDERWAY USING SYNTHETIC DATA

Source(s): MDClone company data, 2022

First diagnostic test to detect risk of pre-term birth

CASE STUDY

Sera Prognostics NASDAQ: SERA

Preterm birth has both immediate and long-term medical, financial, and emotional implications on mothers, babies, and families as a whole. At present, there is no method available to predict premature birth risk. Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better monitor pregnancies, and proactively address risks of adverse pregnancy outcomes.

Sera Prognostics created a platform to discover, develop and commercialize biomarker tests for major pregnancy-related conditions. Sera's first commercial product, the PreTRM® Test, is the only broadly validated, commercially available blood-based biomarker test to predict the risk of preterm birth. Additionally, Sera develops tests for several other pregnancy conditions with the aim of significantly improving maternal and neonatal health and dramatically reducing healthcare costs.

IMPACT PILLARS

- REDUCE COSTS
- PARADIGM SHIFTING BREAKTHROUGHS
- PREDICTIVE & PERSONALIZED MEDICINE

CASE STUDY

Sera Prognostics NASDAQ: SERA

FIRST DIAGNOSTIC TEST TO DETECT RISK OF PRE-TERM BIRTH

1M

ANNUAL GLOBAL NEWBORN DEATHS DUE TO PRETERM BIRTH COMPLICATIONS

$25B

ANNUAL U.S. HEALTHCARE COSTS TO MANAGE PREMATURE BIRTH COMPLICATIONS*

$850M

POTENTIAL TO BE SAVED ANNUALLY IN U.S. INDIVIDUAL AND EMPLOYER-SPONSORED HEALTH PLANS*

10%

REDUCTION

IN NEONATAL INTENSIVE CARE ADMISSIONS*

33%

REDUCTION

IN PRE-TERM BIRTHS <32 WEEKS' GESTATION*

>1

IN 10 BABIES

ARE BORN PREMATURE

Source(s): Grabner M, Burchard J, Nguyen C, Chung H, Gangan N, Boniface JJ, Zupancic JAF, Stanek E. Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. Clinicoecon Outcomes Res. 2021 Sep 14;13:809-820. doi: 10.2147/CEOR.S325094. PMID: 34548799; PMCID: PMC8449551; Sera Prognostics company data, 2022

*Assuming full uptake of Sera's test-and-treat strategy: identifying pregnant women at risk and subsequently enabling evidence-based interventions


Chapter 02

aMoon at a Glance

Purpose-built platform to invest in HealthTech



4
Funds



AUM
$1.3B

Across 31 Investments
Diversified across Digital Health, MedTech, Tools & Diagnostics, and BioPharma

8
co-investments



55
Team Members



As of March 31, 2022

Venture Funds

PLATFORM

- Alpha
- IR & Storytelling
- Finance & Operations
- Legal
- Compliance

VELOCITY I 2019 VINTAGE

AUM $114M

- Early-stage venture formation/Seed/A
- Closed end

GROWTH I I 2018 VINTAGE

AUM $750M

- Late-stage B/C/D
- Closed end

GROWTH II I 2021 VINTAGE

TARGET $750M

- Late-stage B/C/D
- Closed end

EDGE

2022 GOAL $100M I TARGET $300M

- Late-stage crossover*/IPO/public
- Long-only
- Open end**

* Investing in Crossover rounds is subject to the creation of a fund structure - in cooperation with the Israeli tax authoritires - with respect to the tax treatment of non-Israeli LPs in Israel.

** Initial 18 months lockup

aMoon Portfolio

Adicet Bio
ALTRUBIO
ayala targeted therapies
Biolojic Design
biosplice
CartiHeal
CAVOS BIOTECHNOLOGIES
eleos
GraphiteRx
IBEX
KAHR
lin
MDCLONE
METASIGHT
MiNA Therapeutics
MOBILion SYSTEMS, INC.
nanoGhost
NECTINTx
omada
prognomiQ
Satellite BIO
scipher MEDICINE
seer
SERA PROGNOSTICS® The Pregnancy Company®
SOPHiA™
STEALTH
theranica
viracta
zebra MEDICAL VISION

The Breadth and Depth of our Network

Limited Partners

Our investors include large global banks, well known institutional investors, as well as family offices, foundations, and individuals

Portfolio Companies

Completed 31 investments in HealthTech companies since 2018

aMoon Office

We operate out of our office in Ra'anana, Israel

aMoon Team Experience

Our multi-disciplinary team is composed of scientists, physicians, engineers, entrepreneurs and investors with global experience



aMoon Mindset

OUR VALUES

WORK AS A TEAM AND BUILD DEEP, TRUSTED RELATIONSHIPS

- Be approachable, collaborative, and respectful
- Give credit & acknowledge your mistakes

STRIVE FOR PROFESSIONAL EXCELLENCE

- Pursue our mission, relentlessly
- Strive to always be continuously learning
- go the extra mile to exceed our goals

MAKE A POSITIVE IMPACT


- Do well by doing good
- Accelerate cure
- Build growth engines



Chapter 03

Year in Review

Year in Review: 2021



JANUARY

Velocity's top-up to $114m

First Starfinder cohort

NEW INVESTMENT Lin Health

FEBRUARY

Viracta goes public via reverse merger (NASDAQ: VIRX)

NEW INVESTMENT Metasight Diagnostics

Up round - Ibex Medical Analytics

MARCH

NEW INVESTMENT Scipher Medicine

NEW INVESTMENT BioSplice Therapeutics

Biolojic Design announces collaborations with Eli Lilly and Nectar

aMoon Growth II Launched

APRIL

NEW INVESTMENT Sera Prognostics

MAY

MiNA Therapeutics announces $1.25 billion partnership with Eli Lilly

Up round - Nectin Therapeutics

JUNE

NEW INVESTMENT Kahr Medical

Up round - MOBILion

Ibex Medical Analytics granted Breakthrough Device Designation by FDA

NEW INVESTMENT Eleos Mental Systems

aMoon Explorer Program Launched

JULY

SOPHiA Genetics IPO (NASDAQ: SOPH)

Sera Prognostics IPO (NASDAQ: SERA)

AUGUST

Bioventus exercises right to purchase Cartiheal for up to $500 million

SEPTEMBER

NEW INVESTMENT GraphiteRx

OCTOBER

Stealth completes financing round at $3.5 billion post-money valuation

NEW INVESTMENT Cavos BioTech

NOVEMBER

aMoon Annual LP Meeting

Acquisition of Zebra Medical Vision by Nanox Imaging closed

DECEMBER


NEW INVESTMENT Omada Health

Adicet Bio announces positive interim clinical trial results

New Investments in 2021

$168.8M























Chapter 04

Accelerating Cure, Driving Lasting Impact

IMPACT THESIS



Technology has transformed virtually every aspect of our lives. Now, it's healthcare's turn.

aMoon is here to accelerate this transformation.

At aMoon, we partner with exceptional management teams that leverage new, disruptive technologies that make a lasting positive impact and introduce cutting-edge solutions to unmet medical needs.

We invest in companies that share our values and are passionate about fulfilling our vision for the future of healthcare.

OUR IMPACT THESIS

How We Think About & Measure Impact

We assess impact throughout the entire investment cycle; from screening to investing to portfolio monitoring.
We have defined six impact pillars that derive from our mission to accelerate cure.

SAVE & EXTEND LIVES

Save life or meaningfully extend life: innovations that can cure diseases and save lives through breakthrough treatments.

IMPROVE QUALITY OF LIFE

Improve the quality of life for those with chronic diseases: treatments for some of the most challenging unmet needs.

ACCESS TO HEALTHCARE

Better access to healthcare: we back cutting-edge technologies to democratize healthcare and ensure access to affordable, quality health services for all.

REDUCE COSTS

As healthcare costs rise to unsustainable levels we focus on increasing institutions' capacity and cutting costs.

PARADIGM SHIFTING BREAKTHROUGHS

Enabling the development of groundbreaking technologies transforming the way we diagnose and treat severe disease.

PREDICTIVE & PERSONALIZED MEDICINE

Promote predictive and personalized medicine, and new ways of delivering healthcare: from reactive to predictive, from treatment to prevention, from generic to personalized.

aMoon Innovation Index

Velocity

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	ACCESS TO HEALTHCARE	REDUCE COSTS	PARADIGM SHIFTING BREAKTHROUGHS	PREDICTIVE & PERSONALIZED	*IMPACT STAGE
CAVOS BIOTECHNOLOGIES							1
eleos							3
GraphiteRx							3
IBEX							3
lio							▲ 3
METASIGHT							1
nanoGhost							1
NECTINTx							1
Satellite BIO							1


Growth

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	ACCESS TO HEALTHCARE	REDUCE COSTS	PARADIGM SHIFTING BREAKTHROUGHS	PREDICTIVE & PERSONALIZED	*IMPACT STAGE
Adicet Bio							▲ 2
ALTRUBIO							2
ayala							2

*Impact stage **1** Early Development **2** Late Development **3** Early Commercialization **4** Late Commercialization ▲ The company has moved up an impact stage from 2020

aMoon Innovation Index

Growth



**Acquired by Nano-X Imaging Ltd.

***Impact stage** **1** Early Development **2** Late Development **3** Early Commercialization **4** Late Commercialization ▲ The company has moved up an impact stage from 2020

Driving Lasting Impact

We invest in cutting edge technologies and exceptional entrepreneurs who are harnessing groundbreaking science and innovation to transform healthcare.

PORTFOLIO IMPACT TO DATE



*aMoon Growth & Velocity companies

Overcoming Immuno-Oncology therapy resistance by leveraging unique insights into the Nectin pathway

CASE STUDY

Nectin Therapeutics

Despite the unprecedented efficacy of existing immunotherapy agents, most patients either fail to respond or, following encouraging initial response, develop resistance over time.

Nectin Therapeutics discovered novel escape mechanisms and is developing targeted therapies leveraging its unique insights into the Nectin pathway to allow the immune system to effectively target and destroy difficult-to-treat cancers.

IMPACT PILLARS

SAVE & EXTEND LIVES

PARADIGM SHIFTING BREAKTHROUGHS

CASE STUDY

Nectin Therapeutics


OVERCOMING IMMUNO-ONCOLOGY THERAPY RESISTANCE BY LEVERAGING UNIQUE INSIGHTS INTO THE NECTIN PATHWAY

5 assets under development

NECTIN'S NEXT GENERATION ICI'S AND ADC'S REPRESENT A DEEP PIPELINE WITH BOTH MONO AND COMBINATION POTENTIAL.

MD Anderson partnership

THE CANCER FOCUS FUND, AN ONCOLOGY-FOCUSED FUND IN PARTNERSHIP WITH MD ANDERSON, SELECTED NECTIN FOR ITS 3RD INVESTMENT.



>75%

OF SMALL CELL LUNG CANCER PATIENTS OVER-EXPRESS PVR (NECTIN'S LEAD TARGET)

$127B

PROJECTED GLOBAL IMMUNO-ONCOLOGY MARKET BY 2026

80%

OF CANCER PATIENTS DO NOT RESPOND TO APPROVED IMMUNE ONCOLOGY THERAPIES

Q2 2022

LEAD ASSET ENTERING US CLINICAL TRIAL FOR ADVANCED AND METASTATIC SOLID TUMORS.

Source(s): Nectin company data, 2022

CASE STUDY

Satellite Bio

Liver disease represents a major global burden and unmet therapeutic need. Whole and partial liver transplants are the gold standard solutions for liver disease, but persistent donor organ shortage limits the efficacy of liver transplants.

Satellite Biosciences is an early-stage life sciences company leading the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. Satellite Bio's technology is based on two decades of research done in award-winning labs at MIT, Harvard, UPenn, and Boston University.

IMPACT PILLARS

- SAVE & EXTEND LIVES
- IMPROVE QUALITY OF LIFE
- PARADIGM SHIFTING BREAKTHROUGHS

Lab-grown, implantable satellite organs as living therapeutic solutions for serious diseases.

CASE STUDY

Satellite Bio

LAB-GROWN, IMPLANTABLE SATELLITE ORGANS AS LIVING THERAPEUTIC SOLUTIONS FOR SERIOUS DISEASES.



<10%

OF GLOBAL TRANSPLANT NEEDS ARE MET

$230B

MARKET SIZE OF CHRONIC LIVER DISEASES

20 Years

SATELLITE'S LEAD PRODUCT IS BASED ON 20 YEARS OF RESEARCH DONE IN THE LABS OF CO-FOUNDERS DR. SANGEETA BHATIA AND DR. CHRIS CHEN FROM HARVARD & MIT

10+

INDICATIONS THAT COULD BE TREATED WITH SATELLITE BIO'S NOVEL TISSUE THERAPEUTICS

500M

LIVER DISEASE PATIENTS WORLDWIDE

2M


DEATHS PER YEAR ATTRIBUTABLE TO LIVER DISEASE

Source(s): Satellite Bio company data, 2022; Current status of adult liver transplantation: utilization of living donor versus deceases donor graft. Tran & Humar, Current Opinion in Organ Transplantation: 2021-Volume 26

Investment Focus

By partnering with outstanding management teams and global centers of innovation, we push ourselves to simultaneously improve access to care, quality of care, and cost of care.

We partner with entrepreneurs developing proactive, preventive tools that facilitate earlier diagnosis and treatment of disease. We invest in companies that offer personalized approaches to treatment – both on the diagnostic and therapeutic fronts by pairing therapies to a person's biological signature. We are focused on companies that can link better healthcare outcomes with payor economics. We are continuously on the lookout for new healthcare delivery models that facilitate better access to care stemming from the convergence with technology.



*aMoon Growth & Velocity companies

Groundbreaking Research

We believe that breakthrough scientific research drives the most transformative HealthTech innovations. We see our role as co-explorers, partnering with outstanding scientists to redefine the way diseases are studies, diagnosed and treated.



SPONSORED RESEARCH

We jump to the head of the line, sponsoring breakthrough research conducted at leading global academic institutions, in collaboration with major pharma, biotech, medtech and digital multi-nationals.

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE

Roche

COLUMBIA UNIVERSITY

VENTURE FORMATION

Leveraging our company-building skill set, expertise and vast network to co-found new pioneering companies.

nanoGhost

METASIGHT


lio

The Explorer Program

Highly-disruptive, high-impact proposals for sponsored translational breakthrough academic research in three areas we believe are exciting and on the verge of a major transformation

AREAS OF FOCUS


DIGITAL THERAPEUTICS



DISEASES DETECTION & TREATMENT VIA SYNTHETIC BIOLOGY



NOVEL THERAPEUTIC APPROACHES IN FIBROTIC DISEASES



ROCHE-aMoon PARTNERSHIP

StarFinder Digital Innovation Lab

Unique "Build to Buy" Strategic Collaboration Program

Exclusive innovation program for AI-based diagnostics ventures to fast-track ‘Proof of Concept’ (POC) projects based on validated market needs, joint pre-seed investment with an option to invest post POC and access to data & unique expertise.

THEMES



DYNAMIC CANCER TREATMENT

Next generation diagnostic testing



CHRONIC LIVER DISEASES

Diagnosis, prognosis and prediction



DIGITAL & COMPUTATIONAL PATHOLOGY



AI-BASED


Non/minimal invasive respiratory tract sampling



Chapter 05

Unlocking Value, Amplifying Impact

INVESTOR ADDITIONALITY




Trust isn’t just what aMoon means in Hebrew. It’s what we stand for.

We build partnerships with outstanding entrepreneurs and scientists who are transforming the way we diagnose, treat and cure.

aMoon Value Add

As a global fund headquartered in Israel, we connect our portfolio companies to global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.

We tap aMoon's global network to equip entrepreneurs with the expertise, connections, resources, and support they need to accelerate their path to value creation so they can build world leading companies.



Strategic Communications

Raise company profiles by sharpening branding, media, and storytelling strategy.

Building Syndicates & Financing Readiness

Tailored access to top private and public co-investors & Wall Street leaders to broaden investor base and expand network.





Business Development & Strategy

Facilitate introductions to potential customers, collaborators, advisors, and value creation opportunities.

Talent

Leverage our global talent network to identify, engage, and match C-suite & board talent to fill organizational gaps.



aMoon Alpha: Building Bridges

Our Bridges program connects aMoon portfolio companies with key ecosystem players in the healthcare field: building “bridges” between Israel and other global HealthTech hubs. Through these relationships, entrepreneurs are able to sharpen their understanding of market needs, refine product market-fit, and execute operational plans with greater impact and speed.


We help our companies build partnerships with top private and public co-investors, Wall Street leaders, research institutions and payers & provider networks, as well as the largest Biopharma, MedTech and Tech corporations in the world.

Investor Additionality by the Numbers

CAPITAL

We supported

74% | 23 *out of* 31



With


65% conversion rate to:

- *Follow-on investments*
- *Successful introductions to bankers*
- *Support ahead of IPO*
- *Support in M&A process.*

PAYORS & PROVIDERS

We supported

26% | 8 *out of* 31



With


50% conversion rate to:

- *Advanced discussion on pilots with provider networks*
- *Payor offering TS*
- *Potential partnerships*

STRATEGICS

We supported

65% | 20 *out of* 31



With


20% conversion rate to:

- *Strategic work on defining value proposition*
- *Signed collaboration agreements*
- *Intros & Support around M&A*

SCIENCE

We supported

45% | 14 *out of* 31



With


57% conversion rate to:

- *Connections to first customers*
- *Connections to clinical sites*
- *Assembling scientific & clinical advisory boards*
- *Access to bio-samples*

TALENT

We supported

94% | 29 *out of* 31



With


59% conversion rate to:

- *Executive board and senior management placements*
- *Referrals for industry experts and top advisors*
- *Access to exclusive talent networks*

STORYTELLING

We supported

55% | 17 *out of* 31



With

93% conversion rate to:

- *Publications in top tier news outlets*
- *PR support for financing rounds, IPOs, and rebranding initiatives*

Desirable outcomes Ongoing or no developments as of YE2021 No involvement

Our Investment Impact

$2.5 billion

Was raised by our portfolio companies in the public and private rounds after and during our initial investment

Fidelity INVESTMENTS
D1 CAPITAL PARTNERS
GENERAL ATLANTIC
andreessen horowitz
SoftBank
T.RowePrice INVEST WITH CONFIDENCE
BVF PARTNERS L.P.
NOVARTIS
INTERMOUNTAIN VENTURES
Johnson & Johnson INNOVATION JJDC
BRUKER



What Our Portfolio Leadership Says



One of the great aspects of our relationship with aMoon has been the depth and breadth of connections we've been able to make. aMoon helped us to locate an incredible clinical advisor who has been able to pull us right to the center of the transformation happening in pain science.

Abigail Hirsch, PhD
Lin Health Co-Founder & CPO



During diligence, I was asked to present our system to a new hospital in Canada. It felt like a waste of time. But I remember Yair telling me, 'Don't look at it as a test, look at it as an opportunity to open doors'. And here we are today, we've signed a contract with this hospital.

Ziv Ofek
MDClone CEO & Founder



The relationship I built with Tomer (aMoon General Partner) is quite profound and very honest. The first time we met in person, it felt like we'd known each other for ten years.

Jurgi Camblong
SOPHiA CEO & Co-founder



It's been very valuable to get the perspective of a team that reviews company pitches regularly. The experience was productive and insightful, and we were delighted to have the timely and focused support.

Fabian Tenenbaum
Nectin Therapeutics CEO

LEVERAGING THE POWER OF OUR NETWORK TO FOCUS OUR EFFORTS

lin · prognomiQ · STEALTH · eleos · Satellite BIO

ALIGNING WITH THE CEO TO BUILD TRUST-BASED RELATIONSHIPS AND VALUE-BASED AGENDA

SOPHiA™ · KAIA · seer · IBEX

ADDING VALUE THROUGH DILIGENCE

MDCLONE · scipher MEDICINE · MiNA Therapeutics · GraphiteRx

USING STRATEGIC COMMUNICATIONS TO STRENGTHEN MESSAGING AND BRAND

NECTIN Tx · Satellite BIO · METASIGHT · MDCLONE

GraphiteRx

Modern marketplace platform streamlining pharmacy procurement & distribution

CASE STUDY

GraphiteRX

Pharmacy buyers are currently using outdated and unsynchronized technology to procure pharmaceuticals outside of the three primary full-line wholesalers. This process makes it difficult for buyers to manage direct spending and for suppliers to reach the pharmacy buyers.

GraphiteRx's platform provides pharmacies with a one-stop shop to order the medications and supplies they need from outside their full-line wholesaler and helps suppliers sell directly to health systems, pharmacies, and clinics. GraphiteRx is a modern pharmacy marketplace that is transforming healthcare by reimagining how pharmacies and suppliers do business.

IMPACT PILLARS

ACCESS OF HEALTHCARE

REDUCE COSTS

CASE STUDY

GraphiteRX

MODERN MARKETPLACE PLATFORM STREAMLINING PHARMACY PROCUREMENT & DISTRIBUTION



$40B

IN PHARMACEUTICAL SPENDING OUTSIDE FULL-LINE WHOLESALERS

6K

TOTAL NUMBER OF HOSPITALS IN THE U.S.

300+

ACTIVE SUPPLIERS ON THE PLATFORM

1.5K

PHARMA SUPPLIERS IN THE U.S.

Source(s): GraphiteRx company data, 2022

CASE STUDY

Eleos health

The behavioral healthcare industry is extremely overburdened. With pen and paper as the primary tool for keeping patient notes, which are used as the base for diagnoses and recommendations, a more efficient tool is needed to provide actionable insights that enable clinicians to make data-informed decisions and reduce administrative burden.

Eleos Health developed an AI-backed platform that consolidates the entire behavioral care workflow - from documentation to progress notes to compliance administration – all while providing deep clinical insights through session intelligence. Eleos' platform frees clinicians from the time-consuming operational burdens and enbales them to make data-driven decisions and provide better care.

IMPACT PILLARS

ACCESS OF HEALTHCARE

REDUCE COSTS




Powering the future of behavioral health

CASE STUDY

Eleos health

POWERING THE FUTURE OF BEHAVIORAL HEALTH



32%

INCREASE IN THE NUMBER OF AMERICAN ADULTS WHO REPORT STRUGGLING WITH BEHAVIORAL HEALTH ISSUES FOLLOWING THE COVID-19 PANDEMIC

20%

MENTAL HEALTH CLINICIANS SPEND 20% OF THEIR TIME ON ADMINISTRATIVE TASKS

133k

THE MENTAL HEALTH SERVICES ADMINISTRATION ESTIMATES THAT THERE WILL BE A COMBINED SHORTAGE OF 133,000 MENTAL HEALTH COUNSELORS, SOCIAL WORKERS, AND PSYCHOLOGISTS BY 2025

$225B

US SPENDING ON MENTAL HEALTH MARKET SERVICES REACHED 225 BILLION IN 2019, ACCOUNTING FOR NEARLY 5.5% OF ALL HEALTH SPENDING

40%

REDUCTION IN ADMINISTRATIVE BURDEN ON MENTAL HEALTH CLINICIANS

Source(s): Eleos company data, 2022



Chapter 06

Our Impact Management Frameworks

Our Approach to Sustainable Investing

We define impact as the “what”; the areas in which we’re changing, disrupting and making a true difference.

For us, ESG is a roadmap for the “how”; the processes and systems we have in place and how we conduct our business.

ESG and Impact go hand in hand: we envision our work in ESG and Impact running in parallel, complementary to one another. Our impact management strategy focuses on the direct impact we seek to achieve through the products and services we bring to market. The integration of ESG factors into our investment engine and operations, will enable us as investors to mitigate risks and identify value creation opportunities.

Solving for Health & Economic Growth

Our investments contribute to the following UN Sustainable Development goals:

GOOD HEALTH AND WELL-BEING

aMoon is committed to supporting a shift away from high cost, reactive care delivery towards predictive and preventative care that stratifies, flags, and performs proactive outreach to high-risk populations.

Target 3.1
Reduce maternal mortality

Target 3.2
End all preventable deaths under 5 years of age

Target 3.4
Reduce mortality from non-communicable diseases and promote mental health

Target 3.B
Support research, development, and universal access to affordable vaccines and medicines

DECENT WORK AND ECONOMIC GROWTH

As the health-tech industry continues to grow, burgeoning technologies are poised to create economic growth engines for nations around the globe, generate high-paying jobs, and leverage this momentum to improve healthcare systems' efficiency and reduce healthcare costs.

Target 8.1
Sustainable economic growth


Target 8.2
Diversify, innovate and upgrade for economic productivity

Target 8.3
Promote policies to support job creation and growing enterprises

INDUSTRY INNOVATION AND INFRASTRUCTURE

Healthcare's digital convergence will continue to transform the entire life sciences eco-system, offering enhanced capabilities to identify drug targets and conduct drug discovery and development more effectively.

Target 9.5
Enhance research and upgrade industrial technologies



Impact is part of our DNA, it manifests across everything we do

aMOON IS COMMITTED TO THE SDG IMPACT STANDARDS FOR PRIVATE EQUITY FUNDS:

- Contributing positively to sustainable development and achieving the SDGs
- Responsible business practices
- Effective impact management and decision making

STRATEGY

As part of our mission to accelerate cure, positively contributing to sustainable development and achievement the SDGs is inherently at the heart of our purpose and strategy.

MANAGEMENT APPROACH

Integrating impact management into our operations and management approach.

TRANSPARENCY

Disclosing how we contribute to achieving the SDGs through our purpose, strategy, management approach, governance and decision making, and report on our performance.

GOVERNANCE

Our commitment to contributing positively to sustainable development through governance practices and our leadership team.

Source(s): UNDP, 2022

Impact Community

Signatory of:
PRI Principles for Responsible Investment

As of 2022 aMoon is a signatory of the UN PRI, joining the leading international network of institutional investors committed to including environmental, social and governance factors in their investment decision making. The decision to join the PRI follows a yearlong review process to strengthen our approach to sustainable investing.


SOCIAL FINANCE ISRAEL

aMoon engaged Social Finance Israel, a leading ESG consulting firm in Israel, to build an ESG framework for evaluating HealthTech startups in accordance with the IMP 5 Dimensions Impact Assessment.

GITA
THE GLOBAL IMPACT TECH ALLIANCE

aMoon is a member of The Global Tech Alliance (GITA), a global network of impact-tech practitioners, from investors to organizations, working to address UN Sustainable Development Goals through tech innovation.

Sustainable Investing Journey



Integrating Impact & ESG into our Investment Lifecycle

DEAL SCREENING

Evaluating how the company's impact vision aligns with our core impact pillars and contribute to our impact thesis.

INVESTMENT

Asking the company to complete an ESG footprint questionnaire prior to approving an investment.

Discussing potential impact as part of our investment committee's decision-making process.

DUE DILIGENCE

Assessing the company's potential substantial societal impact on longevity and quality of life, scientific progression and better healthcare delivery, alongside substantial value for stakeholders.

Thinking about our investor additionality as we look for more ways to add value to companies already in the due diligence process.

PORTFOLIO MANAGEMENT

Measuring our portfolio progress towards our core impact pillars on an annual basis.

aMoon Governance

ADVISORY COMMITTEE

Each aMoon fund maintains an advisory committee composed of representatives of investors in such fund. Its' primary responsibility is to advise the General Partner regarding certain activities that may represent conflicts of interest between the General Partner and the Limited Partners, and consent of the Advisory Committee is required in order for a fund to take certain actions listed in such fund's limited partnership agreement.

GENERAL PARTNER

Each aMoon fund has a distinct general partner that is responsible for the fund's decisions. The General Partner takes decisions with respect to investment and divestment of investments after receiving the recommendation of the Investment Committee.

INVESTMENT COMMITTEE

Each aMoon fund has an investment committee, which provides its recommendations regarding investment in, and divestments from, portfolio companies. Members of the Investment Committees are appointed by the applicable General Partner, and typically consist of, among others, partners in such fund.

COMPLIANCE PRINCIPLES

At aMoon we believe that a strong ethical framework is inextricably linked to long-term business success. We are therefore committed to conducting our investment management business in accordance with the highest legal and ethical standards in furtherance of our clients' interests and in a manner that is consistent with all applicable laws, rules and regulations.

In order to help aMoon maintain the high level of trust and confidence placed in us by our clients, we have instituted a number of policies governing investment and management activities across the company. These policies, along with the aMoon's Code of Ethics, are intended to:

- Ensure compliance risks are identified, prioritized and managed in a timely and appropriate fashion;
- Establish an environment of accountability that promotes compliance with applicable laws, regulations and internal policies and procedures at all levels across the company;
- Offer a medium for confidential reporting of potential non-compliant or unethical behavior

CONFLICTS OF INTEREST

We recognize the position of trust and confidence that our clients have placed in us, and are driven by the fiduciary duty to place client interests before our own. This fiduciary duty includes an obligation to avoid both actual conflicts of interest and the appearance of any conflicts of interest. To this end, aMoon has adopted a range of policies that seek to reduce and address conflicts of interest. Certain conflicts of interest are addressed by the Advisory Committee, while other conflicts are reduced by strict rules restricting personal investments by aMoon employees in the health-tech sphere. Every employee is made aware of aMoon's policies both in trainings and by exposure to our compliance manual.



Chapter 07

Our People




We are a team of scientists, physicians, entrepreneurs and investors with global experience

who have dedicated our lives to science, medicine, technology, and progress.

aMoon Team

Deep expertise, global experience & trusted relationships.



WORK EXPERIENCE

(prior to joining aMoon)




EDUCATION



73%
HAVE A GRADUATE DEGREE

WORLDWIDE




61%
HAVE LIVED, WORKED, OR STUDIED IN 2+ COUNTRIES

LANGUAGES

Hebrew	Arabic
Italian	Portuguese
French	Japanese
German	Mandarin
Spanish	Russian

aMoon Team


Osnat Hakimi
PhD
Associate
Yaniv Sadka
Associate
Irena Katsman
Chief Financial Officer
Elinor Belkine Michaeli
Director of Operations
Gur Roshwalb
MD, MBA
Partner
Katie Hallagan
IR Manager
Moshic Mor
General Partner
Noah Lasson
VP Compliance
Diamanta Edgar Ronen
Personal Assistant
Yael Tzach
VP Business Development
Jon Bristow
Associate
Reut Shema
PhD
Managing Director
Brachie Sprung
Chief Communications Officer & Head of IR
Roy Wiesner
Managing Director
Noam Waldocs
General Counsel
Yair Schindel
MD
Co-founder & Managing Partner
Erica Bennet
Director of Research
Tomer Berkovitz
PhD
General Partner
Guy Gaash
Analyst Intern
Todd Sone
General Partner
Hila Yarom Roytman
Storytelling & Marketing Manager
Alexis Bolner
IR & Communications Intern
Maya Epstein
Director of People
Lilach Dolev
Personal Assistant
Michal Goren Miller
Chief Compliance Officer
Yaron Daniely
PhD
Partner & Head of aMoon Alpha
Nataly Lipovyak
Senior Bookkeeper
Tamar Farel-Becker
Phd
Associate
Maya Tollman Toledano
Senior Legal Counsel
Yonina Berman
IR & Communications Intern
Avital Adler
PhD
Associate
Uri Kedem
Analyst
Natalie Chazon
Personal Assistant
Yodfat Melzer
Controller
Rebecca Peretz
Personal Assistant
Dor Kalfon
Receptionist
Ohad Hollander
Analyst
Hila Oved
VP Finance
Jonathan Lubash
Analyst
Ido Ashball
Business Development Manager
Joanna Adams
Personal Assistant
Ori Zloczower
MD
Analyst
Yael Shinar
Receptionist
Amit Kassovitz
Receptionist

aMoon Team


Accelerating Cure.
aMoon
Accelerating Cure.
Purpose built platform to invest in HealthTech.
$1B
AUM
60
Team members
30

Disclaimer

This presentation (including all information contained herein) is being delivered to parties for the purposes of learning about aMoon's impact. It is provided on a confidential basis to allow readers to learn more about aMoon (the "Fund").

This presentation is being provided to you for the sole purpose of affording you with background information about the Fund's business. Neither the presentation nor anything contained herein forms the basis of any contract or commitment. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Fund and is qualified in its entirety by the information to be made available by the Fund to persons meeting certain investment criteria and not to the public in general.

It is hereby clarified that the offering of interests in the Fund is a private offering and does not constitute and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), and the interests have not been registered nor is there an intention to register them, under the Israeli Securities Law, or under the laws of any other jurisdiction. Investors in the interests will not be able to rely on such securities law in many matters related to or deriving from their investment in the Fund. The interests will be offered and sold under exemptions provided by the Israeli Securities Law in connection with the foregoing, therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. Neither the Israeli Securities Authority nor the regulatory authority of any other country, state or jurisdiction has approved or will approve this presentation or the interests referred to herein. Any representation to the contrary is unlawful.

Neither the General Partner nor the management company, intend to register as an investment adviser, an investment marketer or an investment portfolio manager under the Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 5755-1995, and neither of them carries insurance as set forth under the aforesaid laws. Nothing in this presentation constitutes legal, accounting or tax advice or individually tailored investment advice. It is further clarified that the interests in the Fund are not being registered under the U.S. Securities Act of 1933. The interests are being offered in a private placement and each investor will be required to make certain representations, including but not limited to (a) that it is an accredited investor as defined in Regulation D under the Securities Act, (b) that it is acquiring an interest in the Fund for its own account, for investment purposes only and not with a view to its distribution, and (c) that it has received or had access to all information it deems relevant to evaluate the merits and risks of the prospective investment. This presentation is not intended for, and does not constitute an offer to sell or the solicitation of an offer to buy, any interests in the Fund, to any person to whom such an offer or solicitation is unlawful or not authorized.

While we have endeavored to ensure that all data herein is accurate, no representation, express or implied, is made as to the accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("Forward Looking Statements"). Such Forward Looking Statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases are outside the control of the Fund and its managers and general partner).

By participating in this presentation or by retaining a copy of this presentation, you agree to be bound by the foregoing limitations.
This presentation (including all information contained herein) is being delivered on a confidential basis.

The presentation is the property of the Fund and no part of the presentation may be disclosed, distributed or reproduced to any third party without the consent of the Fund. The offering of interests in the Fund is a private offering and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. This presentation does not constitute an offer to invest in the Fund.

This document is issued by aMoon Ventures Y. SH. Ltd Company number 515563377 (aMoon) as a Corporate Authorised Representative (AR No. 001292024) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (Polar Advisory). aMoon's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the aMoon Growth Fund II L.P. only to wholesale clients. This document is provided on a confidential, personal and private basis for use only by the recipient as a wholesale client under the Corporations Act 2001 (Cth) and should not be forwarded to others. The information contained in this document is of a general nature only and is not to be taken to contain any financial product advice or recommendation. Nothing in this document is intended as financial product advice and it does not take into account any person's investment objectives, financial circumstances or specific needs. This document is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the aMoon Growth Fund II L.P. aMoon and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.